BioAge Labs (BIOA) vs Fulcrum Therapeutics (FULC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
BioAge Labs (BIOA) has outperformed Fulcrum Therapeutics (FULC) over the past year, gaining 11.8% versus a loss of 60.3%. BioAge Labs is the larger company by market cap ($287.3 million vs $280.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIOA | FULC |
|---|---|---|
| Share price | $6.26 | $3.67 |
| Market cap | $287.31M | $280.01M |
| 1-day change | -0.48% | -0.54% |
| YTD return | -52.68% | -67.55% |
| 1-year return | +11.79% | -60.28% |
| 5-year return | — | -85.88% |
| EPS (TTM) | $-2.39 | $-1.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $25.96 | $15.74 |
| 52-week low | $5.04 | $2.83 |
| Distance from 52-week high | -75.88% | -76.68% |
| Analyst consensus | none | none |
| Avg. price target upside | +469.17% | 0.00% |
| Average volume | 915.59K | 1.56M |
| Shares outstanding | 45.90M | 76.30M |
| Employees | 60 | 9 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BIOA has outperformed FULC by 72.1 percentage points over the past year.
About BioAge Labs
BIOA stock →BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging.
Healthcare · Drug Manufacturers - Specialty & Generic · 60 employees
About Fulcrum Therapeutics
FULC stock →Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia.
Healthcare · Biotechnology · 9 employees
BIOA vs FULC FAQ
Which is bigger, BioAge Labs or Fulcrum Therapeutics?
BioAge Labs (BIOA) is larger, with a market capitalization of $287.31M compared with $280.01M for Fulcrum Therapeutics (FULC).
Which stock has performed better over the past year, BIOA or FULC?
BIOA returned +11.79% over the past 12 months, compared with -60.28% for FULC (price return, excluding dividends). Past performance does not predict future results.
Are BioAge Labs and Fulcrum Therapeutics in the same industry?
Both are in the Healthcare sector, but in different industries: Drug Manufacturers - Specialty & Generic for BioAge Labs and Biotechnology for Fulcrum Therapeutics.